
|Videos|September 23, 2021
Dr. Pavic on masitinib plus docetaxel in first-line mCRPC
Author(s)Urology Times staff
“What we found was the [progression-free survival] value was improved in the subgroup of patients with low [alkaline phosphatase levels],” says Michel Pavic, MD.
Advertisement
Body: In this video, Michel Pavic, MD, discusses the background and findings of the study, “
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
3
FDA approves cefepime and zidebactam for complicated UTI
4
FDA updates in urology: May 2026
5











